UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Medical imaging utilization and associated radiation exposure in children with down syndrome

PloS one, 2023-09, Vol.18 (9), p.e0289957-e0289957

2023

Volltextzugriff (PDF)

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-01, Vol.27 (1), p.e22-e29

2021

Volltextzugriff (PDF)

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Drugs in R&D, 2024-09, Vol.24 (3), p.359-381

2024

Volltextzugriff (PDF)

Primary Renal Lymphoma Presenting as End-Stage Renal Disease

Case reports in medicine, 2017-01, Vol.2017 (2017), p.1-3

2017

Volltextzugriff (PDF)

Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells

Cancer letters, 2007-08, Vol.254 (1), p.119-127

2007

Volltextzugriff (PDF)

Children and adolescents with ALL are taller than expected at diagnosis

Journal of pediatric hematology/oncology, 2014-01, Vol.36 (1), p.16-21

2014

Volltextzugriff (PDF)

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B

Expert review of hematology, 2014-10, Vol.7 (5), p.559-571

2014

Volltextzugriff (PDF)

Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

International journal of oncology, 2012-04, Vol.40 (4), p.1277-1284

2012

Volltextzugriff (PDF)

Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice

International journal of oncology, 2012-12, Vol.41 (6), p.2207-2212

2012

Volltextzugriff (PDF)

Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)

International journal of oncology, 2010-11, Vol.37 (5), p.1307-1313

2010

Volltextzugriff (PDF)

Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)

Cancer letters, 2010-10, Vol.296 (1), p.49-54

2010

Volltextzugriff (PDF)

Oral or parenteral administration of curcumin does not prevent the growth of high-risk t(4;11) acute lymphoblastic leukemia cells engrafted into a NOD/SCID mouse model

International journal of oncology, 2013-02, Vol.42 (2), p.741-748

2013

Volltextzugriff (PDF)

Assessing Safe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia

Journal of pediatric hematology/oncology, 2021-08, Vol.43 (6), p.e880-e885

2021

Volltextzugriff (PDF)

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Blood, 2018-11, Vol.132 (Supplement 1), p.5042-5042

2018

Volltextzugriff (PDF)

End-Stage Renal Disease From Cast Nephropathy in a Teenager With Neuroendocrine Carcinoma

Journal of pediatric hematology/oncology, 2016-07, Vol.38 (5), p.e177-e179

2016

Volltextzugriff (PDF)

Assessing Safe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia

Blood, 2017-12, Vol.130, p.4699-4699

2017

Volltextzugriff (PDF)

BAX 335 Hemophilia B Gene Therapy Phase 1/2 Clinical Trial: Long-Term Safety and Efficacy Follow-up

Blood, 2022-11, Vol.140 (Supplement 1), p.10656-10657

2022

Volltextzugriff (PDF)

Diagnostic X-rays and risk of childhood leukaemia

International journal of epidemiology, 2010-12, Vol.39 (6), p.1628-1637

2010

Volltextzugriff (PDF)

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-01, Vol.25 (1), p.e48-e50

2019

Volltextzugriff (PDF)

Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome

The Journal of pediatrics, 2021-07, Vol.234, p.172-180.e3

2021

Volltextzugriff (PDF)

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Blood, 2018-11, Vol.132 (Supplement 1), p.2486-2486

2018

Volltextzugriff (PDF)

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Blood, 2018-11, Vol.132 (Supplement 1), p.1206-1206

2018

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Acta haematologica, 2024-04, p.1-10

2024

Volltextzugriff (PDF)

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Blood, 2019-11, Vol.134 (Supplement_1), p.1129-1129

2019

Volltextzugriff (PDF)

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.2-3

2020

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(98)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(58)
Humans
(46)
Biological And Medical Sciences
(25)
Hematology
(23)
Male
(20)
Oncology
(20)
Medical Sciences
(18)
Child
(16)
Female
(16)
Pediatrics
(16)
Adolescent
(14)
Animals
(14)
Child, Preschool
(12)
Infant
(11)
Cell Line
(9)
General Aspects
(9)
Fundamental And Applied Biological Sciences. Psychology
(8)
Hemophilia
(8)
Mice
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Medical imaging utilization and associated radiation exposure in children with down syndrome

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Primary Renal Lymphoma Presenting as End-Stage Renal Disease

Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells

Children and adolescents with ALL are taller than expected at diagnosis

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B

Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice

Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)

Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)

Oral or parenteral administration of curcumin does not prevent the growth of high-risk t(4;11) acute lymphoblastic leukemia cells engrafted into a NOD/SCID mouse model

Assessing Safe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

End-Stage Renal Disease From Cast Nephropathy in a Teenager With Neuroendocrine Carcinoma

Assessing Safe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia

BAX 335 Hemophilia B Gene Therapy Phase 1/2 Clinical Trial: Long-Term Safety and Efficacy Follow-up

Diagnostic X-rays and risk of childhood leukaemia

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor

Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Suchergebnisse filtern